Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2025)
Historic Operating Leases for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $8.5 million.
- Artiva Biotherapeutics' Operating Leases fell 2366.49% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 2366.49%. This contributed to the annual value of $10.6 million for FY2024, which is 2062.18% down from last year.
- As of Q3 2025, Artiva Biotherapeutics' Operating Leases stood at $8.5 million, which was down 2366.49% from $9.6 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Operating Leases ranged from a high of $15.5 million in Q2 2024 and a low of $8.5 million during Q3 2025
- For the 3-year period, Artiva Biotherapeutics' Operating Leases averaged around $11.3 million, with its median value being $10.6 million (2024).
- In the last 5 years, Artiva Biotherapeutics' Operating Leases plummeted by 2062.18% in 2024 and then tumbled by 3835.17% in 2025.
- Quarter analysis of 3 years shows Artiva Biotherapeutics' Operating Leases stood at $13.3 million in 2023, then decreased by 20.62% to $10.6 million in 2024, then decreased by 19.4% to $8.5 million in 2025.
- Its Operating Leases was $8.5 million in Q3 2025, compared to $9.6 million in Q2 2025 and $10.3 million in Q1 2025.